

### Declaration of Dominique Schols

I, Dominique Schols, declare as follows:

1. I am the sole inventor of the subject matter of claims to methods to use AMD3100 to treat conditions mediated by CXCR4.

2. I am aware that a document which is a publication by Schols, D., *et al.*, *J. Exp. Med.* (1997) 186:1383-1388 has been cited in the prosecution as a publication that anticipates the present claims. The publication date of this document was less than one year prior to 8 July 1998, the priority date to which these claims are entitled.

3. I am the first listed author on this paper; the co-authors Sofie Scruyf, Jo Van Damme, and José A. Esté worked under my direction. Geoffrey Henson supplied the compound and Erik De Clercq is listed as an author by virtue of his senior position. However, all of the work in the paper is conceptually my own and the other co-authors did not contribute to the concept described in the paper that AMD3100 targets the CXCR4 receptor.


4. There is an additional document, Schols, D., *et al.*, *Antiviral Res.* (1997) 147-156 which describes similar work. This appeared in the August issue of *Antiviral Research*, also less than a year prior to 8 July 1998.

5. My co-authors on this paper are also José A. Esté, Geoffrey Henson and Erik De Clercq. These authors filled the same role in this publication as with respect to the *J. Exp. Med.* paper.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed at LEUVEN, BELGIUM, \_\_\_\_\_ March 2003.  
(City) (State) (Day)



\_\_\_\_\_  
Dominique Schols